Clinical Trial Update: Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine [Phase 3]

View source ↗

Summary

Phase 3 study assessing immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine, sponsored by SK Chemicals; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• 13-valent pneumococcal conjugate vaccine (PCV13) (pneumococcal conjugate vaccine, 13-valent)

Snippet

Sponsor: SK Chemicals Co., Ltd. | Conditions: Pneumococcal Infections | Phase 3 | Status: COMPLETED